NEW YORK--(BUSINESS WIRE)--Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today a publication in Clinical and Translational Science, titled: "Syndication in Science: Curated Collaboration," in collaboration with researchers from Takeda, Regeneron, and Merck.
Digital measures are a major advancement in clinical research and offer continuous, real-time data collection. However, adoption has been slower than anticipated due to time-intensive validation processes, cost, and the need for robust evidence generation. Koneksa’s new data syndication model addresses these challenges by facilitating collaboration between technology providers, biopharmaceutical sponsors, and other key stakeholders to share resources and expertise. This model enables faster study launches, real-time data access, and the accelerated validation of digital measures, which can provide more accurate insights into drug efficacy and patient outcomes.
“The syndication model combines the speed of single sponsor studies with the advantage of having multi-member expertise and risk sharing,” said John Wagner, M.D., Ph.D., Chief Medical Officer, Koneksa. “By fostering a curated collaboration across key stakeholder groups, this syndication model enables real-time data insights, potentially faster study launches, and more efficient validation of digital measures, significantly accelerating the development of novel therapies for patients.”
The syndication model is being evaluated in a 12-month Parkinson’s disease progression study called LEARNS, which evaluates the usability, validity, and reliability of digital health tools. The study uses the Koneksa neuroscience toolkit, combining task-based data collection and continuous monitoring via wearable devices, to track disease progression. The study brings together biopharmaceutical partners, which include Merck and Regeneron to share real-time data and analysis to expedite the validation and adoption of digital measures in clinical trials.
“The LEARNS observational Parkinson’s disease study highlights the potential of the syndication model to transform clinical research,” said Dave Hurry, Chief Data Officer, Koneksa. “By validating digital health technologies through collaboration with multiple stakeholders, we’re advancing reliable, patient-friendly measures for disease progression and treatment response. Digital biomarkers are reshaping drug development, and Koneksa is providing the evidence and community for this technology.”
Data syndication offers a faster, collaborative approach for validating digital health measures. It enables real-time data streaming for quality control and dynamic analysis, reducing study startup times and allowing for ongoing adjustments to study designs. By integrating efforts across multiple organizations, syndication drives innovation and collaboration, making drug discovery more efficient and potentially transforming the future of digital biomarkers in drug development.
For more information about Data Syndication, contact Koneksa at datasyndication@koneksahealth.com. More information on the LEARNS study is available at clinicaltrials.gov (NCT06219629).
About Koneksa
Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Our evidence-based biomarker solutions enable efficient clinical trial designs to help innovative therapies reach patients faster. Koneksa aims to revolutionize treatment effect detection in clinical research and improve patient outcomes. Learn more at koneksahealth.com.
